Clinical Trial Search

Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants

Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Percentage of Participants Achieving Best Overall Response of Complete Response (CR), as Assessed by the Independent Review Committee (IRC) — 83.3 percentage of…

Primary: Progression-Free Survival (PFS) — 4.8; 3.7; 1.8 months — p=<0.0001

Primary: Phase I: Dose Limiting Toxicities (DLT) Rate — 3; 5; 0; 1 Participants

Primary: Progression-Free Survival (PFS) — 8 years

Primary: Median Progression-free Survival (PFS) in Participants Treated With Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab (EPOCH-R) — 23.5…

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With Rituximab — 20 mg

Primary: Number of Participants With Tumor Lysis Syndrome (TLS) Events (Safety Run-in) — 1; 0 Participants

Primary: Number of Participants With Toxicity — 8 participants

Primary: Rate of Immunological Response to Vaccination — 0; 15 participants

Primary: Number of Participants With Adverse Events (e.g. Toxicity) — 28 Participants

Primary: Number of Participants Achieving Complete Remission (CR) (Including Unconfirmed CR [CR(u)]) or Partial Remission (PR) — 19; 8 participants

Primary: Kaplan Meier Estimate for Progression Free Survival (PFS) by Independent Review Committee (IRC) Central Review — 37.6; 22.7 weeks — p=0.012

Primary: Correlation Coefficient Between Change From Baseline in Fluoro-L-thymidine Positron Emission Tomography (FLT-PET) Maximum Standard Uptake Value (SUVmax) and in…

Primary: Progression-free Survival — 90 percentage of participants

Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…

Primary: Overall Response Rate — 92 percentage of patients

Primary: Progression-free Survival at 2 Years — 15 Participants

Primary: Progression Free Survival (PFS) — 27.2; 33.5; 7.8 Months

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Percentage of Participants Who Achieve Disease Control Rate (DCR) Which Includes Complete Response (CR), Complete Response Unconfirmed (CRu), Partial Response (PR) or…

Primary: Objective Response Rate (CR + PR) — 46.7 percentage of participants

Primary: Complete Response — 3; 1; 2; 1 Participants

Primary: Single Agent Efficacy (as Determined by Response Rate) — 1; 2 Participants

Primary: Complete Response (CR) Rate — 0.68 proportion

Primary: Overall Response Rate (ORR) As Assessed By Independent Review Committee — 72 Participants — p=<.0001

Primary: Proportion of Patients Experiencing a Complete Response — .62 Proportion of participants

Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants